Article Type
Review
Published
This article provides an overview of the main pathophysiological characteristics of heart failure with preserved ejection fraction (HFpEF), the considered diverse biological effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in this context and the supporting clinical evidence of SGLT2i in patients with HFpEF with a focus on the EMPEROR-Preserved and DELIVER trials.
